Thromb Haemost 1993; 70(05): 834-837
DOI: 10.1055/s-0038-1649679
Platelets
Schattauer GmbH Stuttgart

Inhibitory Effect of Staphylokinase on Platelet Aggregation

Akira Suehiro
The Second Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
,
Yoshio Oura
The Second Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
,
Motoo Ueda
The Second Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
,
Eizo Kakishita
The Second Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan
› Author Affiliations
Further Information

Publication History

Received 18 March 1993

Accepted after revision 15 June 1993

Publication Date:
05 July 2018 (online)

Summary

We investigated the effect of staphylokinase (SAK), which has specific thrombolytic properties, on human platelet aggregation. Platelet aggregation induced with collagen was observed following preincubation of platelets in platelet-rich plasma (PRP) or washed platelet suspension (WP) with SAK at 37° C for 30 min. SAK inhibited platelet aggregation in PRP only at the highest examined concentration (1 x 10-4 g/ml). Although SAK did not inhibit platelet aggregation in WP which contained fibrinogen, it did when the platelets had been preincubated with SAK and plasminogen. The most effective concentration in WP was 1 x 10-6 g/ml. The effect could be inhibited by adding aprotinin or α2-antiplasmin. The highest generation of plasmin in the same preincubation fluid was detected at 1 x 10-6 g/ml SAK. We concluded that SAK can inhibit platelet aggregation in WP by generating plasmin and/or fibrinogen degradation products, but is only partially effective in PRP because of the existence of α2-antiplasmin.

 
  • References

  • 1 Haber E, Quertermous T, Matsueda GR, Runge MS. Innovative approaches to plasminogen activator therapy. Science 1989; 243: 51-56
  • 2 Collen D, Stamp DC, Gold HK. Thrombolytic therapy. Ann Rev Med 1988; 39: 405-423
  • 3 Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42
  • 4 Bertolino G, Noris P, Previtali M, Gamba G, Ferrario M, Montani N, Balduini CL. Platelet function after in vivo and in vitro treatment with thrombolytic agents. Am J Cardiol 1992; 69: 457-461
  • 5 Torr SR, Winters KJ, Santoro SA, Sobel BE. The nature of interactions between tissue-type plasminogen activator and platelets. Thromb Res 1990; 59: 279-293
  • 6 Fears R, Ferres H, Greenwood HC. Comparison of the effects of streptokinase, t-PA and APS AC on human platelet aggregation in vitro in the absence and presence of aspirin. Thromb Res 1990; 60: 259-268
  • 7 Penny WF, Ware JA. Platelet activation and subsequent inhibition by plasmin and recombinant tissue-type plasminogen activator. Blood 1992; 79: 91-98
  • 8 Yamada Y, Furui H, Furumichi T, Yamauchi K, Yokota M, Saito H. Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator. Am Heart J 1991; 121: 1618-1627
  • 9 Vaughan DE, Houtte EV, Declerck PJ, Collen D. Streptokinase-induced platelet aggregation. Circulation 1991; 84: 84-91
  • 10 Vaughan DE, Mendelsohn ME, Declerck PJ, Houtte EV, Collen D, Loscalzo J. Characterization of the binding of human tissue-type plasminogen activator to platelets. J Biol Chem 1989; 264: 15869-15874
  • 11 Gouin I, Lecompte T, Morel M-C, Lebrazi J, Modderman PW, Kaplan C, Samama MM. In vitro effect of plasmin on human platelet function in plasma. Circulation 1992; 85: 935-941
  • 12 Sakai M, Watanuki M, Matsuo O. Mechanism of fibrin-specific fibrinolysis by staphylokinase: Participation of α2-plasmin inhibitor. Biochem Biophys Res Comm 1989; 162: 830-837
  • 13 Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, Sakai M. Thrombolytic properties of staphylokinase. Blood 1990; 76: 925-929
  • 14 Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemostas 1991; 66: 468-473
  • 15 Lijnen HR, Van HoefB, De CockF, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-11832
  • 16 Lijnen HR, Van HoefB, Matsuo O, Collen D. On the molecular interaptions between plasminogen-staphylokinase, α2-antiplasmin and fibrin. Biochem Biophys Acta 1992; 1118: 144-148
  • 17 Lijnen HR, De CockF, Matsuo O, Collen D. Comparative fibrinolytic and fibrinogenolytic properties of staphylokinase and streptokinase in plasma of different species in vitro. Fibrinolysis 1992; 6: 33-37
  • 18 Sako T. Overproduction of staphylokinase in Escherichia coli and its characterization. Eur J Biochem 1985; 149: 557-563
  • 19 Friberger P, Knös M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-Haemostasis. 1978; 7: 138-145
  • 20 Pasche B, Loscalzo J. Platelets and fibrinolysis. Platelets 1991; 2: 125-134
  • 21 Moroi M, Aoki N. Isolation and characterization of α2-plasmin inhibitor from human plasma. J Biol Chem 1976; 251: 5956-5965
  • 22 Ley tinVL, Misselwitz F, Lyubimova EV, Domogatsky SP. The role of platelet prostanoids and dense granule compounds in initial attachment, spreading and aggregation of platelets on collagen substrates. Thromb Res 1989; 55: 395-406
  • 23 Suehiro A, Higasa S, Ueda M, Oura Y, Nishida Y, Kakishita E. Effect of plasminogen activator on platelet aggregation. In: Current Aspects of Blood Coagulation, Fibrinolysis and Platelets. Shen M-C, Teng C-M, Takada A. (eds). Tokyo: Springer; 1993: 159-164